🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to health experts.

A Global Challenge

Cases of gonorrhoea are increasing around the world, with data suggesting in excess of 82 million new cases each year. Particularly high rates are seen in the African continent and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the face of rising global incidence, the spread of superbugs and the very limited treatment choices currently available.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The global health body has classified it as a "critical concern". Recent surveillance showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Gain Clearance

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Experts hope that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a unique collaborative effort for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This approval marks a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Clinical Trial Results and Global Access

According to data released by a prominent scientific publication, the new drug cured over nine in ten of cases of the STI. This places it at an similar efficacy with the current standard treatment, which involves a dual-drug approach. The research involved nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the ability to license and sell the drug in a wide range of regions with limited resources.

Clinicians treating patients have shared optimism. Having a one-pill regimen such as this is hailed as a "critical tool" for public health efforts. This is considered vital to alleviate the strain of the infection for individuals and to halt the transmission of extremely resistant gonorrhoea worldwide.